Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S442-S447 , March 2004

History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion

  • M Cantarovich

      Affiliations

    • Department of Medicine (M.C., N.G.), Montréal, Québec, Canada
    • Corresponding Author InformationAddress reprint requests to Marcelo Cantarovich, MD, Department of Medicine, Transplantation Program, Royal Victoria Hospital, McGill University Health Center, 687 Pine Avenue West, Ross 2.58, Montréal, Québec, H3A 1A1, Canada.
    • ,
  • J Barkun

      Affiliations

    • Department of Surgery (J.B., R.C., J.T.), Transplant Program, Royal Victoria Hospital, McGill University Health Center, Montréal, Québec, Canada
    • ,
  • N Giannetti

      Affiliations

    • Department of Medicine (M.C., N.G.), Montréal, Québec, Canada
    • ,
  • R Cecere

      Affiliations

    • Department of Surgery (J.B., R.C., J.T.), Transplant Program, Royal Victoria Hospital, McGill University Health Center, Montréal, Québec, Canada
    • ,
  • J.-G Besner

      Affiliations

    • Faculté de Pharmacie (J.G.-B.), Université de Montréal, Montréal, Québec, Canada
    • ,
  • J Tchervenkov

      Affiliations

    • Department of Surgery (J.B., R.C., J.T.), Transplant Program, Royal Victoria Hospital, McGill University Health Center, Montréal, Québec, Canada

References 

  1. Morris PJ. Cyclosporine A. Transplantation. 1981;32:349
  2. Miller LW, O'Connell JB. Long-term use of cyclosporine in cardiac transplantation. Transplant Proc. 1990;22:15
  3. Myers BD, Ross J, Newton L, et al.  Cyclosporine associated chronic nephropathy. N Engl J Med. 1984;311:699
  4. Mihatsch MJ, Thiel G, Spichtin HP, et al.  Morphological findings in kidney transplant after treatment with cyclosporine. Transplant Proc. 1983;4:2821
  5. Platz KP, Mueller AR, Blumhardt G, et al.  Nephrotoxicity following orthotopic liver transplantation. Transplantation. 1994;58:170
  6. Winkler M, Brinkmann C, Jost U, et al.  Long-term side effects of cyclosporine-based immunosuppression in patients after liver transplantation. Transplant Proc. 1994;26:2679
  7. Greenberg A, Egel JW, Thompson ME, et al.  Early and late form of cyclosporine nephrotoxicity (studies in cardiac transplant patients). Am J Kidney Dis. 1987;9:12
  8. Lewis RM, Van Buren CT, Radovancevic B, et al.  Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts (serial renal function in heart and kidney transplant recipients). J Heart Lung Transplant. 1991;10:63
  9. Gonwa TA, Mai ML, Pilcher J, et al.  Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J Heart Lung Transplant. 1992;11:926
  10. Cantarovich M, Fitchett D, Latter D. Cyclosporine trough levels, acute rejection, and renal dysfunction after heart transplantation. Transplantation. 1995;59:444
  11. Ojo AO, Held PJ, Port FK, et al.  Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931
  12. Holt DW, Mueller EA, Kovarick JM, et al.  The pharmacokinetics of Sandimmune Neoral (A new oral formulation of cyclosporine). Transplant Proc. 1994;26:2935
  13. Warrens AN, Salama A, Waters JB, et al.  Comparison of Neoral and Sandimmune preparations in renal transplant patients—improved pharmacokinetics with Neoral. Transplant Proc. 1996;28:2169
  14. Kahan BD. Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation. Transplant Proc. 1996;28:2143
  15. Keown PA. Use of cyclosporine microemulsion (Neoral) in de novo and stable renal transplantation (clinical impact, pharmacokinetic consequences and economic benefits). Transplant Proc. 1996;28:2147
  16. Kovarik JM, Mueller EA, Richard F, et al.  Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation. 1996;62:759
  17. Kahan BD, Dunn J, Fitts C, et al.  The Neoral formulation (improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients). Transplant Proc. 1994;26:2940
  18. Cole E, Keown P, Landsberg D, et al.  Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients (a report of the Canadian Neoral Renal Study Group). Transplantation. 1998;65:505
  19. Foradori AC, Martinez L, Vacarezza A, et al.  Pharmacokinetics of a new galenical formulation of oral cyclosporine A in stable kidney transplanted patients. Transplant Proc. 1994;26:2969
  20. Amante AJ, Kahan BD. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. Transplant Proc. 1996;28:2162
  21. Keown P, Landsberg D, Halloran P, et al.  A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation. 1996;62:1744
  22. Gaspari F, Anedda MF, Signorini O, et al.  Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. J Am Soc Nephrol. 1997;8:647
  23. Cantarovich M, Besner JG, Barkun JS, et al.  Two hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant. 1998;12:243
  24. Roubenoff R, Drew H, Moyer M, et al.  Oral cimetidine improves the accuracy and precision of creatinine clearance in lupus nephritis. Ann Intern Med. 1990;113:501
  25. Hilbrands LB, Artz MA, Wetzels JFM, et al.  Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int. 1991;40:1171
  26. Cantarovich M, Giannetti N, Cecere R, et al: Single time point predictors of cyclosporine microemulsion and of mycophenolic acid area-under-the-curve (AUC0-12 hr) in long-term heart transplant patients. Am J Transplant 3(Suppl 5):168, 2003
  27. Cantarovich M, Elstein E, de Varennes B, et al.  Clinical benefit of Neoral dose monitoring with cyclosporine 2-hour post dose levels compared to trough levels in stable heart transplant patients. Transplantation. 1999;68:1839
  28. Delgado D, Cusimano RJ, Feindel C, et al.  Monitoring of cyclosporine 2-hr post-dose and trough levels in heart transplantation. J Heart Lung Transplant. 2002;21:102
  29. Cantarovich M, Quantz M, Elstein E, et al.  Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction. Transplant Proc. 2000;32:446
  30. Billingham ME, Cary NR, Hammond ME, et al.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection (Heart Rejection Study Group). J Heart Transplant. 1990;6:587
  31. Cantarovich M, Giannetti N, Cecere R. Impact of cyclosporine 2-hour level and of mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplant. 2003;17:144
  32. Cantarovich M, Giannetti N, Cecere R: Relationship between endomyocardial biopsy score and cyclosporine 2-hour peak levels during the first year after heart transplantation. Clin Transplant (in press), 2004
  33. Levy G, Burra P, Cavallari A, et al.  Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation. 2002;73:953
  34. International Neoral Renal Transplantation Study Group . Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant. 2002;2:157
  35. Cooney GF, Johnston A. Neoral C-2 monitoring in cardiac transplant patients. Transplant Proc. 2001;33:1572
  36. Cantarovich M, Barkun JS, Tchervenkov JI, et al.  Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation. 1998;12:1621
  37. Levy G, Smith R, O'Grady C, et al.  Long term follow up of maintenance liver transplant patients converted to C2 cyclosporine using Neoral immunosuppression. Am J Transplant. 2002;3:370
  38. Levy G, Lilly LB, Grant DR, et al.  Once daily dosing with Neoral utilizing C2 monitoring in maintenance liver transplant patients. Am J Transplant. 2003;5:422
  39. Grant D, Kneteman N, Tchervenkov J, et al.  Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection (results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8)). Transplantation. 1999;67:1133
  40. Baraldo M, Risaliti A, Bresadola F, et al.  Circadian variations in cyclosporine C2 concentrations during the first 2 weeks after liver transplantation. Transplant Proc. 2003;35:1449
  41. Batiuk TD, Pazderka F, Enns J, et al.  Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest. 1995;96:1254
  42. Sindhi R, LaVia MF, Paulling E, et al.  Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen. Transplantation. 2000;69:432

PII: S0041-1345(04)00005-3

doi: 10.1016/j.transproceed.2004.01.004

Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S442-S447 , March 2004

Article Tools